drugset
drugset / Trial / NCT01903200

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

NCT01903200 ↗

Phase 1 Completed 16 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelOther

Summary

The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in elderly patients with major depressive disorder (MDD).

Timeline

Start
2010-02
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule — Oral

Indications

major depressive disorder